Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
Status:
Withdrawn
Trial end date:
2019-09-19
Target enrollment:
Participant gender:
Summary
This phase I trial studies the best dose and side effects of tazemetostat in treating
patients with solid tumors or B-cell lymphomas with liver dysfunction that have spread to
other places in the body or cannot be removed by surgery. Tazemetostat may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth.